Navigation Links
Gerresheimer Achieves Sales Target for 2009
Date:2/9/2010

    DUSSELDORF, Germany, February 9 /PRNewswire-FirstCall/ --
    - Profit Margin Better Than Expected

    - Sales on like-for-like basis almost at prior year level (-1.5 percent)
    - Adjusted EBITDA margin of 19.2 percent (on like-for-like basis) better
      than expected
    - CEO Dr. Axel Herberg: "We have demonstrated our stability and
      profitability in a difficult environment."
    - Outlook for 2010: sales increase of 2 to 4 percent and Adjusted EBITDA
      margin of mid 19 percent

In the economically challenging environment of the past year, Gerresheimer AG has achieved its sales target and turned in a better operating margin than expected.

Group sales in the past financial year (to the end of November) reached EUR1 billion. The pharma business, which now accounts for around three quarters of Group sales, again ensured a slight growth in sales in 2009. In contrast, the cyclical fields of cosmetics and Life Science Research suffered a fall in sales. On a like-for-like basis, i.e. excluding the Technical Plastics Systems business which was sold as per July 1, 2009, sales were 1.5 percent down on the prior year (forecast -1.5 to -2.5 percent).

The good operating margin (Adjusted EBITDA Margin), which at 19.2 percent exceeded the forecast of around 18.5 percent on a like-for-like basis, was achieved through early realignment of production capacity and cost reductions. Overall, however, there was a year-on-year fall in the operating result (Adjusted EBITDA) at EUR185.9m (2008: EUR206.4m). In contrast, net income rose substantially from EUR4.5m to EUR7.0m because of reduced one-off expenses. As a result, earnings per share increased from EUR0.02 to EUR0.18.

Gerresheimer f
'/>"/>

SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Gerresheimer has Passed the Turning Point
2. Mirixa Australia Achieves Six Month Milestones
3. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
4. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
5. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
10. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
11. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Decision Resources Group finds that, for the treatment ... France , Germany , ... and the United Kingdom ) hold ... beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). ... first-line LABA/ICS FDC in the treatment of asthma with ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- "North America Orthopedic Braces ... data on the North America Orthopedic Braces and Supports ... dollars, and volume (in units) and average price data ... Knee Braces and Supports , Ankle Braces and ... Upper Extremities Braces and Supports. ...
(Date:7/24/2014)... -- Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... "Innovation Tank" – a forum designed to give pediatric ... or product solution to a panel of acclaimed judges ... accelerate the innovation and bring it to market. ... 31, will be moderated by Daymond John ...
Breaking Medicine Technology:Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... SHANGHAI, July 19, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... biotechnology and medical device R&D outsourcing company with operations ... it will release financial results for the second quarter ... on Wednesday, August 10, 2011 (which will be Thursday ...
... 2011 ,   - ... Aims to Improve Overall Interdisciplinary Care , and Transform Patient ... CPM Resource Center (CPM), a leader in developing,clinical decision support ... Services, a not-for-profit,health system committed to providing services to communities ...
Cached Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release 2Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 2Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 3Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 4
(Date:7/24/2014)... 24, 2014 (HealthDay News) -- A new formulation of ... snorting or injecting the drug has been approved by ... ER and made by Purdue Pharma, the pill is ... drug that blocks the euphoric effects of oxycodone. The ... snorted, dissolved or injected, according to the FDA. ...
(Date:7/24/2014)... for the 4th Annual National Venous Interventional Summit ... VEINS is an established Venous Endovascular Interventional Strategies ... primary aim is to provide a "How To" ... are interested in advancing their knowledge and skills ... developing their own comprehensive venous interventional program. Topics ...
(Date:7/24/2014)... ACRIA & AMIDA CARE TO COHOST WHITE HOUSE ... Save the Dates: August 7th & August 8th* ... Dialogue for Life” forums this August, led by Douglas Brooks, ... National AIDS Policy (ONAP). This will be a wonderful opportunity ... AIDS organizations, consumers and advocates to advance the National HIV/AIDS ...
(Date:7/24/2014)... 24, 2014 National Analysts Worldwide, the ... it will operate globally under the name, NAXION ... woman-owned Employee Stock Ownership Plan (ESOP) organization led by ... Ph.D . The firm guides market strategy in ... , Said McDonald, “We wanted our name to ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 For the first time ... the United States. The Scottish singer first became a known musical ... Talent. Her first song on the show was “I Dreamed a ... has released five studio albums since her time on the reality ... perform in front of her American fans. The tour will kick ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... developed at UC Irvine that made paralyzed rats walk again ... in humans. , The U.S. Federal Drug Administration has approved ... by Hans Keirstead, co-director of the UCI Sue and Bill ... patients with acute spinal cord injury. , Geron Corp. of ...
... decreased 3.7 points to 45.7 in December, according to the latest ... Harris Interactive(R) on behalf of Spherion Corporation, indicates that workers are ... to find a new job. , , Results ... Sixty-six percent of workers believe ...
... San Antonio Officials with The University of Texas ... $1.2 million gift from the Robert J. Kleberg, Jr. ... to purchase a second generation aberration corrected electron microscope. ... nanotechnology researchers develop new cancer therapies and treatments that ...
... company, will it be a good deal or a bad deal? Fintan Walton, ... companies. , ... Oxford, UK (PRWEB) January 23, 2009 -- If Pfizer and Wyeth merge ... a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially ...
... scientists will gather in Canberra this week for the ... a homecoming for the ANS which was formally created ... input from ANU. , A total of 535 presentations ... made by neuroscientists throughout the conference, revealing the latest ...
... Your Smile to Fit Your Life -CINCINNATI, Jan. 23 ... advanced innovation in teeth whitening technology: New Crest Whitestrips ... strip to users, teeth, allowing them to easily talk ... The secure fit comes off clean after whitening, ...
Cached Medicine News:Health News:UCI behind world's first embryonic stem cell study in humans 2Health News:Texas Employment Report: Employee Confidence Index Drops 2Health News:UTSA receives $1.2 million gift from Kleberg Foundation 2Health News:Pfizer - Wyeth: Good Deal – Bad Deal? 2Health News:The world's best brains descend on Canberra 2Health News:Crest Whitestrips Introduces a Revolutionary New Teeth Whitening Technology 2Health News:Crest Whitestrips Introduces a Revolutionary New Teeth Whitening Technology 3
... Growth hormone (GH) is a monomeric protein ... anterior pituitary gland. GH is released from ... pulsatile manner under the regulatory control of ... [1]. The timing and frequency of GH ...
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
... potent naturally occurring androgen produced from ... 5a-reductase [1]. The concentrations of ... tissues, including genital skin and hair ... apparent association with the nuclear membrane. ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Medicine Products: